The CNS CRO is a private laboratory that specializes in neurological diseases and offers pre-clinical and clinical testing services. Its extensive capabilities include animal and cell models and expertise in cognitive and behavioral assessments. The company also conducts pre-clinical trials using proprietary compounds for neurodegenerative diseases.
Vial CRO is a leading CNS CRO, providing integrated functional readouts in neuro-pharmacology and other related fields. The company’s data is derived from a combination of in vitro and in vivo CNS electrophysiology and behavioral tests, all powered by a strong college of expert scientists. The company’s data can be used for rapid lead selection and validation of target engagement.
Clinical trial solutions
Neurology and CNS CROs face a wide range of complex clinical trial needs. The complexity of these studies makes the development and implementation of clinical trial solutions critical. A neurology clinical trial needs specialized expertise that can only be acquired through a dedicated, multidisciplinary team. Fortunately, there are CROs that specialize in these trials and are able to provide the right solution for your needs.
The Vial CRO provides a modular suite of clinical trial services that minimizes bias, variability, and human error in CNS studies. The company uses an integrated approach of clinical expertise and specialized technology to reduce clinical endpoint error rates by up to 85%.
Preclinical models
To help accelerate development of new treatments for neurological diseases, CNS-CRO has bolstered its animal model capabilities by acquiring a licensing agreement with the University of Prince Edward Island (UPEI). The new technologies will enhance CNS-CRO’s preclinical development and testing capabilities. With the new models, CNS-CRO hopes to distinguish itself from other CROs.
A number of challenges remain in establishing clinical trials for novel drugs for neurological and psychiatric disorders. First, it can take decades for new drugs to reach patients with complex neurological disorders. Furthermore, animal models are not very predictive of drug efficacy due to inherent differences between human and animal anatomy and cell types. Another challenge is that the success rate of clinical trials is very low. Furthermore, lack of phenotype and endotyping is a key limiting factor in validating targets. Lack of biomarkers is another issue that hinders the effective development of new treatments for neurological disorders.
In addition, the use of animals in neuroscience research is regulated by a variety of laws. The lack of harmonization in these laws poses a challenge to international research. Furthermore, lack of cross-training and collaboration among different disciplines has limited the ability to develop breakthrough drugs for neurological and CNS disorders.
To improve the robustness of preclinical data, the industry is making efforts to improve publication policies. This will improve data transparency and reliability. Furthermore, the Preclinical Data Forum is developing an online platform that will facilitate the disclosure of large amounts of pre-competitive information in a transparent manner.
Increasing patient-centered research is another important strategy to advance drug development. Focus on predicting outcomes is crucial to the drug development pipeline, because it can help define informative steps in the development pipeline. In addition, a focus on de-risking research can help identify therapeutic targets, which in turn can help improve early-stage drug development.
Biomarker-driven clinical execution
Precision offers biomarker-driven clinical execution to bio-pharmaceutical companies looking to optimize their drug development processes. The company has expertise in neurology and CNS clinical trials. Their services include a range of services, including biomarker development and analysis, data management, and quality assurance.
Integrated data management – Biomarker-driven clinical trials generate enormous datasets across multiple assays. Consequently, biomarker-driven CROs must break through data silos to create a comprehensive data picture and make timely decisions. Precision’s multiomic QuartzBio(r) data platform enables clinical trial teams to analyze diverse biological data to uncover hidden insights.
Patient engagement
Patient engagement is one of the best practices in generating evidence that is relevant to patients and consumers. Understanding engagement practices and supporting them is an important policy issue. It can improve research design, conduct, and uptake. It also helps inform resource allocation and policies. Patient engagement can help improve the effectiveness of clinical trials and reduce costs for research teams.
The PICOR Institute was created to fund comparative effectiveness research, which compares and contrasts the effectiveness of clinical interventions in real-world settings. The PICOR Institute encourages patient engagement in these projects. There are several ways to implement patient engagement in clinical trials. First, patients and caregivers can be involved in research.
Second, patient engagement can contribute to the feasibility, acceptability, and rigor of clinical trials. This is because engagement is a way to make studies more relevant to patients and improve research alignment. This is especially important for large-scale clinical trials where the results could potentially affect millions of patients.
The goal of patient engagement in clinical trials is to improve patient satisfaction, retention, and adherence. Patients and caregivers are involved in the design and development of their treatments, which increases the likelihood of positive outcomes. Patient-centricity can also reduce costs and improve quality of care.
The conference aimed to educate patients and the clinical research community about patient engagement in clinical trials. It featured workshops, large and small group discussions, and presentations from patient advocates, clinical trial staff, and research investigators. Overall, attendees aimed to learn more about patient engagement in clinical trials for neurological disorders.
Read also: Cardiology CRO – An Overview of the Different Types of CROs
Vial CRO
As a One-Stop-Shop CNS CRO, Vial CRO offers functional readouts in neuro-pharmacology. Its member companies include diverse CNS platforms that allow industrial clients to leverage complementary data for research. The company’s mission is to accelerate CNS and pain research programs through a comprehensive portfolio of services.
Vial CRO is a member of Biocom California, the largest life science association in California. The association helps its members to connect with the life-science community, drives public policy, and cultivates a vibrant environment for the life science industry. Vial CRO benefits from this close association. Additionally, the CNS CRO is a member of the French-American Chamber of Commerce in San Diego, which brings a global network of professionals to the table.
With the rising prevalence of neurological disorders, the need for CROs offering CNS clinical services has increased. The Parkinson’s Foundation’s Prevalence Project, for example, estimates that there will be 1.2 million people living with Parkinson’s disease in North America by 2030. As a result of this increase in neurological research, the CRO market will grow as well.
Neurology contract research organizations are a cost-effective way to conduct clinical development and clinical trials. CROs also have regulatory affairs professionals that ensure compliance throughout the development process. As a result, outsourcing clinical trials to a CRO helps clients reduce their risk of regulatory violations.
Nasson Science
Nasson Science is a CNS CRO that targeting the global market. Its partners include European Biotech and Korea Biotech. As a result, Nasson Science is well-versed in the development of new CNS drugs. The company also specializes in the efficacy evaluation in animal models.
It has also published papers on CNS disorders. Its research is funded by numerous institutions. The company was founded in 2005 and is located in Seoul, South Korea. Its researchers are committed to conducting clinical trials for a variety of diseases. Its clinical trials are available in more than thirty countries.
Nasson Science has a long history of supporting drug development, with over 20 years of experience in the field. Sweeney was head of Charles River’s Finland site in 2009, and the company has been partnered with Cerebricon for over 15 years. Sweeney’s extensive experience in preclinical research prompted him to suggest the creation of a CNS CRO.
Heather Taylor joined the CNS Support Team in September 2016. She has an AS degree in Business Administration and is currently pursuing her Bachelor’s degree. She has extensive data management experience with numerous sponsors. Previously, she was an assistant site director at a phase one research center. She is passionate about improving the quality of research in the healthcare industry.
Precision
Precision for Medicine is a biomarker-driven clinical research organization that supports life sciences companies with biomarker-driven therapies. This organization has received four CRO Leadership Awards, based on surveys of bio-pharmaceutical sponsors. This recognition is a sign of excellence and dedication to patient-centrality.
Precision’s expertise is in identifying and developing biomarkers to monitor neuronal function in disease models. They use neuron-derived endoscopes isolated from patients’ blood to perform downstream biochemical assays. This approach facilitates the identification of novel diagnostic and prognostic biomarkers. Precision provides full-service global CNS clinical trials for emerging and mid-stage biopharmaceutical companies.
CenExel Clinical Research
CenExel Clinical Research is a network of 13 clinical research centers in the U.S. that focuses on neurology and pain. The company also conducts research on vaccines and immunology. In addition to these disciplines, CenExel has research centers in dermatology, psychiatry, and ethnic bridging studies.
CenExel Clinical Research has recently acquired California Neuroscience Research, a clinical research facility based in Los Angeles that has nearly two decades of experience in neurological and psychiatric studies. CNR has experience in research on Alzheimer’s disease, migraine pain, and depression.
The Los Angeles-based CenExel CNR facility specializes in CNS-related trials, enabling it to conduct trials in the second-largest metro area in the U.S. The research team at CenExel CNR is led by Dr. Tom Shiovitz, who has 30 years of experience in CNS clinical trial research. The team is committed to providing high-quality research data and treating patients safely and comfortably.
Neurodyn Inc.
Neurodyn is a biotech company focused on neuroprotection and early treatment of neurological diseases. Its research focuses on identifying and validating bioactives found in nature and converting them into prescription drugs. The company has several drug candidates in its pipeline, including its ND1004 neuroprotectant, which is in its early stages of development. The company was founded in 2009 and is headquartered in Vancouver, British Columbia.
Neurodyn’s pipeline is advancing, and the company is confident that Memogain(r) will be a breakthrough Alzheimer’s drug. The company is now in the process of advancing this Alzheimer’s drug through a fast-track regulatory process in the US and Europe. The company also plans to pursue clinical trials of this drug in the U.S. in late 2013.
The company’s drug candidates are focused on the substantia nigra, a brain region implicated in PD. The company has developed a proprietary factor that can enhance PGRN expression in this region. The company will then administer this factor to mice four weeks after PGRN has been elevated. In the following test, the mice will be exposed to the Parkinsonism-inducing neurotoxin MPTP and tested for dopamine cell loss and loco-motor dysfunction.